Works matching DE "LENALIDOMIDE"

Results: 288
    1
    2

    Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6).

    Published in:
    Annals of Hematology, 2025, v. 104, n. 4, p. 2317, doi. 10.1007/s00277-025-06355-5
    By:
    • Fuhrmann, Stephan;
    • Nickelsen, Maike;
    • Hasenkamp, Justin;
    • Hüttmann, Andreas;
    • Dreyling, Martin;
    • Kiehl, Michael;
    • Salwender, Hans;
    • Placzek, Marius;
    • Hilgers, Reinhard;
    • Schmitz, Norbert;
    • Glass, Bertram
    Publication type:
    Article
    3

    Treatment patterns of patients with triple-class exposed refractory/relapsed multiple myeloma in Poland -- preliminary results of multicentre observational POMOST study.

    Published in:
    Acta Haematologica Polonica, 2025, v. 56, n. 1, p. 48, doi. 10.5603/ahp.103294
    By:
    • Grząśko, Norbert;
    • Wałachowska, Beata;
    • Dytfeld, Dominik;
    • Gołos, Aleksandra;
    • Ziarkiewicz, Mateusz;
    • Waszczuk-Gajda, Anna;
    • Węglarz, Patryk;
    • Czyżewska, Maria;
    • Olszewska-Szopa, Magdalena;
    • Tyczyńska, Agata;
    • Dołęga-Talacha, Karolina;
    • Jurczyszyn, Artur;
    • Butrym, Aleksandra;
    • Urbanowicz, Alina;
    • Druzd-Sitek, Agnieszka
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11

    Large-scale real-life analysis of survival and usage of therapies in multiple myeloma.

    Published in:
    Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01474-w
    By:
    • Lopez-Muñoz, N.;
    • Hernández-Ibarburu, G.;
    • Alonso, R.;
    • Sanchez-Pina, J. M.;
    • Ayala, R.;
    • Calbacho, M.;
    • Cuellar, C.;
    • Cedena, M. T.;
    • Jimenez, A.;
    • Iñiguez, R.;
    • Pedrera, M.;
    • Cruz, J.;
    • Meloni, L.;
    • Pérez-Rey, D.;
    • Serrano, P.;
    • de la Cruz, J.;
    • Martinez-Lopez, J.
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20

    Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00882-y
    By:
    • Tan, Carlyn Rose;
    • Derkach, Andriy;
    • Nemirovsky, David;
    • Ciardiello, Amanda;
    • Diamond, Benjamin;
    • Hultcrantz, Malin;
    • Hassoun, Hani;
    • Mailankody, Sham;
    • Shah, Urvi;
    • Maclachlan, Kylee;
    • Patel, Dhwani;
    • Lahoud, Oscar B.;
    • Landau, Heather J.;
    • Chung, David J.;
    • Shah, Gunjan L.;
    • Scordo, Michael;
    • Giralt, Sergio A.;
    • Lesokhin, Alexander;
    • Usmani, Saad Z.;
    • Landgren, Ola
    Publication type:
    Article
    21
    22

    A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00854-2
    By:
    • de Jonge, A. Vera;
    • van Werkhoven, Erik;
    • Dinmohamed, Avinash G.;
    • Nijland, Marcel;
    • Zwinderman, Aeilko H.;
    • Bossuyt, Patrick M.;
    • Veldhuis, Martine S.;
    • Rutten, Emma G. G. M.;
    • Mous, Rogier;
    • Vermaat, Joost S. P.;
    • Sandberg, Yorick;
    • de Jongh, Eva;
    • Bilgin, Yavuz M.;
    • Boersma, Rinske;
    • Koene, Harry;
    • Kersten, Marie José;
    • de Jong, Daphne;
    • Chamuleau, Martine E. D.
    Publication type:
    Article
    23

    Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00724-3
    By:
    • Gurnari, Carmelo;
    • Piciocchi, Alfonso;
    • Soddu, Stefano;
    • Bonanni, Fabrizio;
    • Scalzulli, Emilia;
    • Niscola, Pasquale;
    • Di Veroli, Ambra;
    • Piccioni, Anna Lina;
    • Piedimonte, Monica;
    • Maiorana, Gianluca;
    • Salutari, Prassede;
    • Cicconi, Laura;
    • Santopietro, Michelina;
    • Gumenyuk, Svitlana;
    • Sarlo, Chiara;
    • Fenu, Susanna;
    • Tafuri, Agostino;
    • Latagliata, Roberto;
    • Fianchi, Luana;
    • Criscuolo, Marianna
    Publication type:
    Article
    24
    25

    Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.

    Published in:
    2022
    By:
    • Nooka, Ajay K.;
    • Kaufman, Jonathan L.;
    • Rodriguez, Cesar;
    • Jakubowiak, Andrzej;
    • Efebera, Yvonne;
    • Reeves, Brandi;
    • Wildes, Tanya;
    • Holstein, Sarah A.;
    • Anderson Jr, Larry D.;
    • Badros, Ashraf;
    • Shune, Leyla;
    • Chari, Ajai;
    • Pei, Huiling;
    • Cortoos, Annelore;
    • Patel, Sharmila;
    • Bartlett, J. Blake;
    • Vermeulen, Jessica;
    • Lin, Thomas S.;
    • Richardson, Paul G.;
    • Voorhees, Peter
    Publication type:
    Letter
    26

    Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41408-021-00593-2
    By:
    • Dimopoulos, Meletios A.;
    • Schjesvold, Fredrik;
    • Doronin, Vadim;
    • Vinogradova, Olga;
    • Quach, Hang;
    • Leleu, Xavier;
    • Montes, Yolanda Gonzalez;
    • Ramasamy, Karthik;
    • Pompa, Alessandra;
    • Levin, Mark-David;
    • Lee, Cindy;
    • Mellqvist, Ulf Henrik;
    • Fenk, Roland;
    • Demarquette, Hélène;
    • Sati, Hamdi;
    • Vorog, Alexander;
    • Labotka, Richard;
    • Du, Jichang;
    • Darif, Mohamed;
    • Kumar, Shaji
    Publication type:
    Article
    27

    The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM).

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 9, p. 1, doi. 10.1038/s41408-021-00548-7
    By:
    • Ho, Matthew;
    • Zanwar, Saurabh;
    • Kapoor, Prashant;
    • Gertz, Morie;
    • Lacy, Martha;
    • Dispenzieri, Angela;
    • Hayman, Suzanne;
    • Dingli, David;
    • Baudi, Francis;
    • Muchtar, Eli;
    • Leung, Nelson;
    • Kourelis, Taxiarchis;
    • Warsame, Rahma;
    • Fonder, Amie;
    • Hwa, Lisa;
    • Hobbs, Miriam;
    • Kyle, Robert;
    • Rajkumar, S. Vincent;
    • Kumar, Shaji
    Publication type:
    Article
    28

    Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 9, p. 1, doi. 10.1038/s41408-021-00542-z
    By:
    • Desai, Sanjal H.;
    • LaPlant, Betsy;
    • Macon, William R.;
    • King, Rebecca L.;
    • Wang, Yucai;
    • Inwards, David J.;
    • Micallef, Ivana;
    • Johnston, Patrick B.;
    • Porrata, Luis F.;
    • Ansell, Stephen M.;
    • Habermann, Thomas M.;
    • Witzig, Thomas E.;
    • Nowakowski, Grzegorz S.
    Publication type:
    Article
    29
    30

    Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network.

    Published in:
    Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1162990
    By:
    • Antonioli, Elisabetta;
    • Pilerci, Sofia;
    • Attucci, Irene;
    • Buda, Gabriele;
    • Gozzetti, Alessandro;
    • Candi, Veronica;
    • Simonetti, Federico;
    • Del Giudice, Maria Livia;
    • Ciofini, Sara;
    • Staderini, Michela;
    • Grammatico, Sara;
    • Buzzichelli, Alessandra;
    • Messeri, Maria;
    • Bocchia, Monica;
    • Galimberti, Sara;
    • Vannucchi, Alessandro M.
    Publication type:
    Article
    31

    Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multicentered study in China.

    Published in:
    Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1028571
    By:
    • Zhe Zhuang;
    • Ying Tian;
    • Lei Shi;
    • Dongmei Zou;
    • Ru Feng;
    • Wei-wei Tian;
    • Hong Yu;
    • Fei Dong;
    • Aijun Liao;
    • Yanping Ma;
    • Qinhua Liu;
    • Shuangjiao Liu;
    • Hongmei Jing;
    • Rong Fu;
    • Liang-ming Ma;
    • Hui Liu;
    • Wanling Sun;
    • Li Bao;
    • Yin Wu;
    • Wenming Chen
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39
    40

    Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 14, p. 2225, doi. 10.1080/10428194.2023.2259528
    By:
    • Ip, Andrew;
    • Petrillo, Alessandra;
    • Pia, Alexandra Della;
    • Lee, Geeny G.;
    • Gill, Sarvarinder;
    • Varughese, Tony;
    • Zenreich, Joshua;
    • Gutierrez, Martin;
    • Zhang, Jiayu;
    • Ahn, Jaeil;
    • Bharani, Vishnu;
    • Nejad, Ava S.;
    • Pascual, Lauren;
    • Feldman, Tatyana A.;
    • Leslie, Lori A.;
    • Goy, Andre H.
    Publication type:
    Article
    41
    42
    43
    44
    45

    Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 9, p. 2126, doi. 10.1080/10428194.2022.2062347
    By:
    • Lahoud, Oscar B.;
    • Landau, Heather;
    • Nguyen, James;
    • Devlin, Sean;
    • Lendvai, Nikoletta;
    • Weltz, Jonathan;
    • Ayorinde, Tumininu;
    • Chung, David J.;
    • Lesokhin, Alexander M.;
    • Kewalramani, Tarun;
    • Korde, Neha;
    • Mailankody, Sham;
    • Landgren, Ola;
    • Giralt, Sergio;
    • Comenzo, Raymond L.;
    • Hassoun, Hani
    Publication type:
    Article
    46

    Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 7, p. 1566, doi. 10.1080/10428194.2022.2043299
    By:
    • Tettamanti, Sarah;
    • Rotiroti, Maria Caterina;
    • Giordano Attianese, Greta Maria Paola;
    • Arcangeli, Silvia;
    • Zhang, Ronghua;
    • Banerjee, Priyanka;
    • Galletti, Giovanni;
    • McManus, Sheighlah;
    • Mazza, Massimiliano;
    • Nicolini, Fabio;
    • Martinelli, Giovanni;
    • Ivan, Cristina;
    • Veliz Rodriguez, Tania;
    • Barbaglio, Federica;
    • Scarfò, Lydia;
    • Ponzoni, Maurilio;
    • Wierda, William;
    • Gandhi, Varsha;
    • Keating, Michael;
    • Biondi, Andrea
    Publication type:
    Article
    47

    Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 6, p. 1407, doi. 10.1080/10428194.2022.2030477
    By:
    • Bahlis, Nizar J.;
    • Siegel, David S.;
    • Schiller, Gary J.;
    • Samaras, Christy;
    • Sebag, Michael;
    • Berdeja, Jesus;
    • Ganguly, Siddhartha;
    • Matous, Jeffrey;
    • Song, Kevin;
    • Seet, Christopher S.;
    • Acosta-Rivera, Mirelis;
    • Bar, Michael;
    • Quick, Donald;
    • Anz, Bertrand;
    • Fonseca, Gustavo;
    • Chung, Weiyuan;
    • Lee, Kim;
    • Mouro, Jorge;
    • Agarwal, Amit;
    • Reece, Donna
    Publication type:
    Article
    48

    Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 3, p. 710, doi. 10.1080/10428194.2021.1992763
    By:
    • Gaballa, Mahmoud R.;
    • Ma, Junsheng;
    • Tanner, Mark R.;
    • Al-Juhaishi, Taha;
    • Bashir, Qaiser;
    • Srour, Samer A.;
    • Saini, Neeraj Y.;
    • Ramdial, Jeremy L.;
    • Nieto, Yago;
    • Murphy, Regan;
    • Rezvani, Katayoun;
    • Tang, Guilin;
    • Lee, Hans C.;
    • Patel, Krina K.;
    • Kaufman, Gregory P.;
    • Manasanch, Elisabet E.;
    • Ullah, Muhammad R.;
    • Kebriaei, Partow;
    • Thomas, Sheeba K.;
    • Weber, Donna M.
    Publication type:
    Article
    49
    50

    Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 1, p. 199, doi. 10.1080/10428194.2021.1971217
    By:
    • Komrokji, Rami;
    • Melody, Megan;
    • al Ali, Najla;
    • Chan, Onyee;
    • Klimek, Virginia;
    • Ball, Brian J.;
    • Sekeres, Mikkael A.;
    • Lucas, George;
    • Maciejewski, Jaroslaw P.;
    • Sallman, David A.;
    • Padron, Eric;
    • Kuykendall, Andrew;
    • Lasho, Terra;
    • Al-Kali, Aref;
    • Naqvi, Kiran;
    • Steensma, David P.;
    • Garcia-Manero, Guillermo;
    • Patnaik, Mrinal M.
    Publication type:
    Article